Loading
A phase 1/2 trial of XNW5004, Enzalutamide in prostate cancer, run by Evopoint Biosciences Inc., now recruiting.
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT06702995 by Evopoint Biosciences Inc., with 307 participants planned, started 2023-04-19 and due to reach its primary completion in 2026-05-13. Interventions recorded: XNW5004, enzalutamide. Conditions listed: Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares XNW5004, Evopoint Biosciences.
Shares XNW5004, Evopoint Biosciences.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares XNW5004, Evopoint Biosciences.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/